LCTX

Lineage Cell Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Lineage Cell Therapeutics sales and earnings growth
LCTX Growth
Low
  • Revenue Y/Y↑ 24.05%
  • EPS Y/Y↓ -163.64%
  • FCF Y/Y↑ 9.46%
Lineage Cell Therapeutics gross and profit margin trends
LCTX Profitability
Fair
  • Gross margin ↑ 97.80%
  • EPS margin↓ -625.50%
  • ROIC↑ 3452.30%
Lineage Cell Therapeutics net debt vs free cash flow
LCTX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Lineage Cell Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗